News|Videos|November 16, 2026

Pharmacists Key to Mavacamten REMS, Interaction Checks in Teens

Joseph Rossano, MD, MS, outlines how pharmacists support the mavacamten REMS, dose adjustments, and interaction screening for adolescents with oHCM.

In an interview with Pharmacy Times, Joseph Rossano, MD, MS, FAAP, FACC, chief of cardiology at Children’s Hospital of Philadelphia, discussed the role of pharmacists in caring for adolescents with obstructive hypertrophic cardiomyopathy (oHCM) who receive long-term mavacamten (Camzyos; Bristol Myers Squibb), as well as the questions that remain about the therapy. Rossano emphasized that mavacamten is part of a Risk Evaluation and Mitigation Strategy (REMS) program designed to ensure safe use, including confirming that ventricular function remains preserved. In the SCOUT-HCM study, he noted there were no drug interruptions due to deteriorating function. However, doses may need adjustment over time, and mavacamten can interact with other medications, so pharmacists play a critical role in assessing whether newly started drugs are safe to use with it and whether dosing should change. He also described pharmacists as a trusted resource for families with questions they did not raise in the doctor’s office.

Looking ahead, Rossano pointed to encouraging signals that the heart may be favorably remodeling, including improved diastolic function, marked reductions in troponin and natriuretic peptides, and reduced wall thickness. Still, follow-up spanning years to decades is needed, along with real-world data in larger populations. He expressed hope that more targeted therapies for pediatric patients will follow.


Related to this article